遺伝子検出市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2023年～2030年）- 技術別、エンドユーザー別、地域別（北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカ）

自己免疫疾患の有病率が世界的に上昇し続けていることから、世界の遺伝子検出の市場規模は大きな成長が見込まれています。より効率的な遺伝子検出法に対する需要の高まりが市場拡大の原動力となっており、RT-PCRのような高度な技術が市場をリードしています。

当レポートでは、世界の遺伝子検出市場について調査し、市場の概要とともに、技術別、手法別、疾患別、エンドユーザー別、地域別動向、および市場に参入する企業の競合動向などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

• 市場の定義とセグメンテーション
• 市場力学
  • 促進要因
  • 抑制要因
  • 市場機会マトリックス
• ポーターのファイブフォース分析
• 規制ガイドライン
• COVID-19の影響分析

第3章 世界の遺伝子検出市場の見通し、2018年～2030年

• 世界の遺伝子検出市場の見通し、技術別、金額（100万米ドル）、2018年～2030年
• 世界の遺伝子検出市場の見通し、手法別、金額（100万米ドル）、2018年～2030年
• 世界の遺伝子検出市場の見通し、疾患別、金額（100万米ドル）、2018年～2030年
• 世界の遺伝子検出市場の見通し、エンドユーザー別、金額（100万米ドル）、2018年～2030年
• 世界の遺伝子検出市場の見通し、地域別、金額（100万米ドル）、2018年～2030年

第4章 北米の遺伝子検出市場の見通し、2018年～2030年

第5章 欧州の遺伝子検出市場の見通し、2018年～2030年

第6章 アジア太平洋の遺伝子検出市場の見通し、2018年～2030年

第7章 その他の地域の遺伝子検出市場の見通し、2018年～2030年

第8章 競合情勢

• 企業の市場シェア分析
• 企業プロファイル
  • Abbott Laboratories
  • Progenity, Inc.
  • Thermo Fischer Scientific
  • Invitae Corporation
  • Ambry Genetics
  • Biocartis Group NV
  • Eurofins Genomics LLC
  • Myriad Genetics, Inc.
  • Siemens Healthineers
  • その他

第9章 付録

The global gene detection market is expected to experience significant growth as the prevalence of autoimmune diseases continues to rise worldwide. Various gene detection methods are being utilized for the identification and categorization of hereditary factors contributing to autoimmune diseases such as rheumatoid arthritis, type 1 diabetes, scleroderma, multiple sclerosis, psoriasis, lupus, and Crohn's disease. The growing demand for more efficient gene detection methods is driving the market's expansion, with advanced techniques like RT-PCR leading the way.

Opportunities Abound in Oncology

The COVID-19 pandemic has accelerated the growth of the gene detection market, with an increasing need for rapid gene detection tests for COVID-19 diagnosis. Additionally, the field of oncology has become a highly attractive area for gene detection research. Multiple cancer-specific gene detection techniques are in development, aligning with the rising prevalence of cancer worldwide. Preventive diagnosis and personalized medicine are gaining momentum, creating a conducive environment for advancements in gene detection methods. With the International Agency for Research on Cancer estimating new cancer incidences to reach 30 million by 2040, gene detection is set to play a significant role in oncology.

Gene Detection Market Continues to Witness Primacy of North America

The growing interest in ancestral analysis is driving demand for gene detection studies, particularly in North America. The region also experiences notably high prevalence of autoimmune diseases, with around 24 million individuals living with such conditions in the US alone, according to the National Institute of Environmental Health Sciences (NIH). This high prevalence has led to an increasing demand for advanced gene detection techniques in developing economies as well. Gene detection kits are gaining popularity as a viable solution to reduce the overall rate of autoimmune disease prevalence and subsequent healthcare expenditure.

The gene detection market in North America stands strong due to the presence of key market players and a rising number of product approvals from the US FDA. Companies engaged in research and development are introducing innovative gene detection methods to the market, further reinforcing North America's position as a global leader in the gene detection market.

Competition Analysis - Global Gene Detection Market

The upcoming report will provide insights into the competitive landscape of the global gene detection market, profiling prominent players and offering exclusive information on their strategic and financial performance. Some of the profiled companies include F Hoffmann-La Roche, Abbott Laboratories, BioRad Laboratories, Danaher, and Illumina Inc.

Table of Contents

1. Executive Summary

• 1.1. Global Gene Detection Market Outlook, 2018 - 2030 (US$ Million)
• 1.2. Global Gene Detection Market Incremental Opportunity, 2018 - 2030 (US$ Million)
• 1.3. Key Industry Trends

2. Market Overview

• 2.1. Market Definitions and Segmentations
• 2.2. Market Dynamics
  • 2.2.1. Drivers
    • 2.2.1.1. Driver 1
    • 2.2.1.2. Driver 2
  • 2.2.2. Restraints
    • 2.2.2.1. Restraint 1
    • 2.2.2.2. Restraint 2
  • 2.2.3. Market Opportunities Matrix
• 2.3. Porters Five Forces Analysis
• 2.4. Regulatory Guidelines
• 2.5. Covid-19 Impact Analysis

3. Global Gene Detection Market Outlook, 2018 - 2030

• 3.1. Global Gene Detection Market Outlook, by Technique, Value (US$ Mn), 2018 - 2030
  • 3.1.1. Key Highlights
    • 3.1.1.1. Polymerase Chain Reaction
    • 3.1.1.2. Microarray
    • 3.1.1.3. Next Generation Sequencing
    • 3.1.1.4. Other
  • 3.1.2. BPS Analysis/Market Attractiveness Analysis
• 3.2. Global Gene Detection Market Outlook, by Method, Value (US$ Mn), 2018 - 2030
  • 3.2.1. Key Highlights
    • 3.2.1.1. Molecular
    • 3.2.1.2. Biochemical
    • 3.2.1.3. Chromosomal
  • 3.2.2. BPS Analysis/Market Attractiveness Analysis
• 3.3. Global Gene Detection Market Outlook, by Disease, Value (US$ Mn), 2018 - 2030
  • 3.3.1. Key Highlights
    • 3.3.1.1. Genetic Disease
    • 3.3.1.2. Cancer
    • 3.3.1.3. Cardiovascular
    • 3.3.1.4. Cognitive Dysfunction
    • 3.3.1.5. Others
  • 3.3.2. BPS Analysis/Market Attractiveness Analysis
• 3.4. Global Gene Detection Market Outlook, by End User, Value (US$ Mn), 2018 - 2030
  • 3.4.1. Key Highlights
    • 3.4.1.1. Hospitals & Clinics
    • 3.4.1.2. Diagnostic Laboratories
    • 3.4.1.3. Academic & Research Institutes
    • 3.4.1.4. Others
  • 3.4.2. BPS Analysis/Market Attractiveness Analysis
• 3.5. Global Gene Detection Market Outlook, by Region, Value (US$ Mn), 2018 - 2030
  • 3.5.1. Key Highlights
    • 3.5.1.1. North America
    • 3.5.1.2. Europe
    • 3.5.1.3. Asia Pacific
    • 3.5.1.4. Rest of the World
  • 3.5.2. BPS Analysis/Market Attractiveness Analysis

4. North America Gene Detection Market Outlook, 2018 - 2030

• 4.1. North America Gene Detection Market Outlook, by Technique, Value (US$ Mn), 2018 - 2030
  • 4.1.1. Key Highlights
    • 4.1.1.1. Polymerase Chain Reaction
    • 4.1.1.2. Microarray
    • 4.1.1.3. Next Generation Sequencing
    • 4.1.1.4. Others
  • 4.1.2. BPS Analysis/Market Attractiveness Analysis
• 4.2. North America Gene Detection Market Outlook, by Method, Value (US$ Mn), 2018 - 2030
  • 4.2.1. Key Highlights
    • 4.2.1.1. Molecular
    • 4.2.1.2. Biochemical
    • 4.2.1.3. Chromosomal
  • 4.2.2. BPS Analysis/Market Attractiveness Analysis
• 4.3. North America Gene Detection Market Outlook, by Disease, Value (US$ Mn), 2018 - 2030
  • 4.3.1. Key Highlights
    • 4.3.1.1. Genetic Disease
    • 4.3.1.2. Cancer
    • 4.3.1.3. Cardiovascular
    • 4.3.1.4. Cognitive Dysfunction
    • 4.3.1.5. Others
  • 4.3.2. BPS Analysis/Market Attractiveness Analysis
• 4.4. North America Gene Detection Market Outlook, by End User, Value (US$ Mn), 2018 - 2030
  • 4.4.1. Key Highlights
    • 4.4.1.1. Hospitals & Clinics
    • 4.4.1.2. Diagnostic Laboratories
    • 4.4.1.3. Academic & Research Institutes
    • 4.4.1.4. Others
  • 4.4.2. BPS Analysis/Market Attractiveness Analysis
• 4.5. North America Gene Detection Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
  • 4.5.1. Key Highlights
    • 4.5.1.1. U.S.
    • 4.5.1.2. Canada
  • 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Gene Detection Market Outlook, 2018 - 2030

• 5.1. Europe Gene Detection Market Outlook, by Technique, Value (US$ Mn), 2018 - 2030
  • 5.1.1. Key Highlights
    • 5.1.1.1. Polymerase Chain Reaction
    • 5.1.1.2. Microarray
    • 5.1.1.3. Next Generation Sequencing
    • 5.1.1.4. Others
  • 5.1.2. BPS Analysis/Market Attractiveness Analysis
• 5.2. Europe Gene Detection Market Outlook, by Method, Value (US$ Mn), 2018 - 2030
  • 5.2.1. Key Highlights
    • 5.2.1.1. Molecular
    • 5.2.1.2. Biochemical
    • 5.2.1.3. Chromosomal
  • 5.2.2. BPS Analysis/Market Attractiveness Analysis
• 5.3. Europe Gene Detection Market Outlook, by Disease, Value (US$ Mn), 2018 - 2030
  • 5.3.1. Key Highlights
    • 5.3.1.1. Genetic Disease
    • 5.3.1.2. Cancer
    • 5.3.1.3. Cardiovascular
    • 5.3.1.4. Cognitive Dysfunction
    • 5.3.1.5. Others
  • 5.3.2. BPS Analysis/Market Attractiveness Analysis
• 5.4. Europe Gene Detection Market Outlook, by End User, Value (US$ Mn), 2018 - 2030
  • 5.4.1. Key Highlights
    • 5.4.1.1. Hospitals & Clinics
    • 5.4.1.2. Diagnostic Laboratories
    • 5.4.1.3. Academic & Research Institutes
    • 5.4.1.4. Others
  • 5.4.2. BPS Analysis/Market Attractiveness Analysis
• 5.5. Europe Gene Detection Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
  • 5.5.1. Key Highlights
    • 5.5.1.1. Germany
    • 5.5.1.2. France
    • 5.5.1.3. U.K.
    • 5.5.1.4. Italy
    • 5.5.1.5. Spain
    • 5.5.1.6. Rest of Europe
  • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Gene Detection Market Outlook, 2018 - 2030

• 6.1. Asia Pacific Gene Detection Market Outlook, by Technique, Value (US$ Mn), 2018 - 2030
  • 6.1.1. Key Highlights
    • 6.1.1.1. Polymerase Chain Reaction
    • 6.1.1.2. Microarray
    • 6.1.1.3. Next Generation Sequencing
    • 6.1.1.4. Others
  • 6.1.2. BPS Analysis/Market Attractiveness Analysis
• 6.2. Asia Pacific Gene Detection Market Outlook, by Method, Value (US$ Mn), 2018 - 2030
  • 6.2.1. Key Highlights
    • 6.2.1.1. Molecular
    • 6.2.1.2. Biochemical
    • 6.2.1.3. Chromosomal
  • 6.2.2. BPS Analysis/Market Attractiveness Analysis
• 6.3. Asia Pacific Gene Detection Market Outlook, by Disease, Value (US$ Mn), 2018 - 2030
  • 6.3.1. Key Highlights
    • 6.3.1.1. Genetic Disease
    • 6.3.1.2. Cancer
    • 6.3.1.3. Cardiovascular
    • 6.3.1.4. Cognitive Dysfunction
    • 6.3.1.5. Others
  • 6.3.2. BPS Analysis/Market Attractiveness Analysis
• 6.4. Asia Pacific Gene Detection Market Outlook, by End User, Value (US$ Mn), 2018 - 2030
  • 6.4.1. Key Highlights
    • 6.4.1.1. Hospitals & Clinics
    • 6.4.1.2. Diagnostic Laboratories
    • 6.4.1.3. Academic & Research Institutes
    • 6.4.1.4. Others
  • 6.4.2. BPS Analysis/Market Attractiveness Analysis
• 6.5. Asia Pacific Gene Detection Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
  • 6.5.1. Key Highlights
    • 6.5.1.1. China
    • 6.5.1.2. Japan
    • 6.5.1.3. India
    • 6.5.1.4. South Korea
    • 6.5.1.5. Australia & New Zealand
    • 6.5.1.6. Rest of Asia Pacific
  • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Rest of the World Gene Detection Market Outlook, 2018 - 2030

• 7.1. Rest of the World Gene Detection Market Outlook, by Technique, Value (US$ Mn), 2018 - 2030
  • 7.1.1. Key Highlights
    • 7.1.1.1. Polymerase Chain Reaction
    • 7.1.1.2. Microarray
    • 7.1.1.3. Next Generation Sequencing
    • 7.1.1.4. Others
  • 7.1.2. BPS Analysis/Market Attractiveness Analysis
• 7.2. Rest of the World Gene Detection Market Outlook, by Method, Value (US$ Mn), 2018 - 2030
  • 7.2.1. Key Highlights
    • 7.2.1.1. Molecular
    • 7.2.1.2. Biochemical
    • 7.2.1.3. Chromosomal
  • 7.2.2. BPS Analysis/Market Attractiveness Analysis
• 7.3. Rest of the World Gene Detection Market Outlook, by Disease, Value (US$ Mn), 2018 - 2030
  • 7.3.1. Key Highlights
    • 7.3.1.1. Genetic Disease
    • 7.3.1.2. Cancer
    • 7.3.1.3. Cardiovascular
    • 7.3.1.4. Cognitive Dysfunction
    • 7.3.1.5. Others
  • 7.3.2. BPS Analysis/Market Attractiveness Analysis
• 7.4. Rest of the World Gene Detection Market Outlook, by End User, Value (US$ Mn), 2018 - 2030
  • 7.4.1. Key Highlights
    • 7.4.1.1. Hospitals & Clinics
    • 7.4.1.2. Diagnostic Laboratories
    • 7.4.1.3. Academic & Research Institutes
    • 7.4.1.4. Others
  • 7.4.2. BPS Analysis/Market Attractiveness Analysis
• 7.5. Rest of the World Gene Detection Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
  • 7.5.1. Key Highlights
    • 7.5.1.1. Latin America
    • 7.5.1.2. Middle East & Africa
  • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Competitive Landscape

• 8.1. Company Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1. Abbott Laboratories
    • 8.2.1.1. Company Overview
    • 8.2.1.2. Financial Overview
    • 8.2.1.3. Technique Portfolio
    • 8.2.1.4. Recent Developments
  • 8.2.2. Progenity, Inc.
  • 8.2.3. Thermo Fischer Scientific
  • 8.2.4. Invitae Corporation
  • 8.2.5. Ambry Genetics
  • 8.2.6. Biocartis Group NV
  • 8.2.7. Eurofins Genomics LLC
  • 8.2.8. Myriad Genetics, Inc.
  • 8.2.9. Siemens Healthineers
  • 8.2.10. Others

9. Appendix

• 9.1. Research Methodology
• 9.2. Report Assumptions
• 9.3. Acronyms and Abbreviations